Signal Pathway Related Mechanism of Vein Graft Failure in Coronary Artery Bypass Grafting
-
摘要:
目的 探索动脉旁路移植术后静脉桥再狭窄形成的信号通路机制。 方法 40只家兔随机分2组，假手术组和模型组，假手术组分离颈静脉、颈动脉，不做移植，模型组游离颈静脉，截取一段颈静脉方向调转后与颈动脉做端侧吻合，结扎两吻合口间的颈动脉，建立动脉旁路移植兔模型，移植后2 d、2周假手术组取出颈静脉，模型组取出移植静脉，肉眼观察，组织切片HE染色量化管腔狭窄程度，免疫组化检测p-p38表达水平，进行对比分析。 结果 与假手术组比较，模型组移植静脉2周后管腔显著性狭窄（P < 0.05），静脉移植后2 d、2周p-p38表达均显著性升高（P < 0.05），其中移植后2 d显著高于移植2周（P < 0.05）。 结论 冠状动脉旁路移植静脉桥再狭窄信号传导机制可能通过p38-MAPK通路。 Abstract:Objective To explore the signal pathway of vein graft failure in coronary artery bypass grafting. Methods 40 rabbits were randomly divided into two groups. Group A was sham operation group; Group B was model group in which rabbit model of CABG was established. The jugular vein in group A and the graft vein group B was removed 2 days and 2 weeks after the vein grafting, and pathological section was used to quantify lumen stenosis, immunohistochemistry was used to detect the phosphorylated p38, and the indexes were comared. Results Compared with group A, the degree of luminal stenosis of group B were significantly higher in 2 weeks after vein graft （P < 0.05）. The expression of p-p38 in vein graft tissue of group B were significantly higher than group A in 2 days and 2 weeks after vein grafting, p-p38 were significantly higher 2 days than 2 weeks after vein grafting in group B （P < 0.05）. Conclusion The mechanism of vein graft failure in CABG might be related to the p38 MAPK signal pathway. -
Key words:
- Coronary artery bypass graft（CABG） /
- Vein graft failure /
- Signal pathway /
- p38 MAPK /
- Rabbit
-
图 3 各组兔静脉组织中 p-p38MAPK 表达（×20）
A：假手术组（术后2 d）；B：模型组（术后2 d）；C：假手术组（术后2周）；D：模型组（术后2周）。
Figure 3. p-p38 MAPK expression in vein tissues of the rabbits in each group （× 20）
图 4 各组兔静脉组织中p-p38 MAPK表达OD值
A：假手术组（术后2 d）；B：模型组（术后2 d）；C：假手术组（术后2周）；D：模型组（术后2周）。与A组比较，▲P < 0.05；与C组比较，△P < 0.05；与B组比较，*P < 0.05。
Figure 4. OD value of p-p38 MAPK expression in vein tissues of the rabbits in each group
表 1 管腔狭窄程度比较（
$\bar x \pm s$ ）Table 1. Comparison of the stenosis of lumen（
$\bar x \pm s$ ）组别 移植2 d（%） 移植2周（%） 假手术组 16.4 ± 5.4 17.8 ± 8.2 模型组 17.3 ± 6.2 31.3 ± 10.5* F 0.121 10.305 P 0.732 0.005 与假手术组比较，*P < 0.05。 
下载: 导出CSV
-
[1] DeStephan C M,Schneider D J. Antiplatelet therapy for patients undergoing coronary artery bypass surgery[J]. Kardiol Pol,2018,76(6):945-952. doi: 10.5603/KP.a2018.0111 [2] Gao Ge,Zheng Zhe,Pi Yi,et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center,randomized,controlled trial[J]. J Am Coll Cardiol,2010,56(20):1639-1643. doi: 10.1016/j.jacc.2010.03.104 [3] 郭军雄,汪斌,马丽,等. p38 MAPK在腹泻型肠易激综合征大鼠中的变化及其免疫调控作用[J]. 中国实验动物学报,2019,21(6):709-715. [4] Sousa-Uva M,Neumann F J,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur J Cardiothorac Surg,2019,14(14):1435-1534. doi: 10.1093/ejcts/ezy289 [5] Velazquez E J,Lee K L,Jones R H,et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy[J]. N Engl J Med,2016,374(16):1511-1520. doi: 10.1056/NEJMoa1602001 [6] Spadaccio C,Benedetto U. Coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention(PCI)in the treatment of multivessel coronary disease:quo vadis?-a review of the evidences on coronary artery disease[J]. Ann Cardiothorac Surg,2018,7(4):506-515. doi: 10.21037/acs.2018.05.17 [7] Khan Y,Cheema M A,Abdullah H M A,et al. Great saphenous vein stump:a risk factor for superficial/deep venous thrombosis and an indication for prophylactic anticoagulation?-a retrospective analysis[J]. Community Hosp Intern Med Perspect,2019,9(6):473-476. doi: 10.1080/20009666.2019.1655626 [8] McKavanagh P,Yanagawa B,Zawadowski G,et al. Management and prevention of saphenous vein graft failure:a review[J]. Cardiol Ther,2017,6(2):203-223. doi: 10.1007/s40119-017-0094-6 [9] Gaudino M,Benedetto U,Fremes S,et al. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery[J]. N Engl J Med,2018,378(22):2069-2077. doi: 10.1056/NEJMoa1716026 [10] 张浒,钟佳冀,黄宏波,等. 灯盏花素对冠脉搭桥术移植静脉保护作用的实验[J]. 昆明医科大学学报,2019,40(11):26-29. doi: 10.3969/j.issn.1003-4706.2019.11.005 [11] Cao B J,Wang X W,Zhu L,et al. Dedicator of cytokinesis 2 silencing therapy inhibits neointima formation and improves blood flow in rat vein grafts[J]. J Mol Cell Cardiol,2019,128(3):134-144. [12] Sun Y,Kang L,Li J,et al. Advanced glycation end products impair the functions of saphenous vein but not thoracic artery smooth muscle cells through RAGE/MAPK signalling pathway in diabetes[J]. J Cell Mol Med,2016,20(10):1945-1955. doi: 10.1111/jcmm.12886 [13] Cuadrado A,Nebreda A R. Mechanisms and functions of p38 MAPK singalling[J]. Biochem J,2010,429(3):403-417. doi: 10.1042/BJ20100323 [14] Ge J J,Zhao Z W,Zhou Z C,et al. p38 MAPK inhibitor,CBS3830 limits vascular remodelling in arterialised vein grafts[J]. Heart Lung Circ,2013,22(9):751-758. doi: 10.1016/j.hlc.2013.02.006 -
点击查看大图
图(4) / 表(1)
计量
- 文章访问数: 4045
- HTML全文浏览量: 2112
- PDF下载量: 24
- 被引次数: 0
